GlassScriptPhysician profile
James L Sechler
NPI 1710921374
$2,333.46
in general payments reported to CMS, 2019-2025
24 companies · $680 in 2025
The $680 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $103 · 2021: $63.16 · 2022: $243 · 2023: $402 · 2024: $539 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,621.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $486.40 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $310.30 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $286.91 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.23 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $158.11 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $120.71 | 2023-2025 | Farxiga, Wainua, Bevespi Aerosphere |
| Medtronic, INC. | $113.99 | 2024-2025 | Hawkone, Corevalve Evolut R |
| Merck Sharp & Dohme LLC | $89.40 | 2021-2023 | Verquvo |
| Amgen INC. | $73.21 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $70.79 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $56.13 | 2019-2021 | |
| Atricure, INC. | $51.05 | 2023-2025 | Synergy Ablation System |
| Lexicon Pharmaceuticals, INC. | $47.63 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $44.32 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $40.10 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $31.09 | 2022-2025 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $30.91 | 2019 | |
| Lundbeck LLC | $24.24 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $19.70 | 2023 | Arcalyst |
| Abbott Laboratories | $18.92 | 2019 | |
| Lilly USA, LLC | $18.51 | 2025 | Zepbound |
| Astellas Pharma US INC | $18.16 | 2021 | |
| Impulse Dynamics (USA) INC. | $17.62 | 2025 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sechler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.